Complex disorders, such as bipolar disorder (BD), likely result from the influence of both common and rare susceptibility alleles. While common variation has been widely studied, rare variant discovery has only recently become feasible with next-generation sequencing.
genetic causes of BD has proved challenging. Numerous genome-wide linkage scans have been performed in BD, but the limited replication across studies suggests that variants of major effect are unlikely to exist. On the other hand, genome-wide association studies of BD have recently implicated a number of variants of small effect in very large samples. 2 While an important role for rare single-nucleotide variants in complex diseases has been proposed on theoretical grounds, 3, 4 empirical data have only recently begun to emerge.
In autism, large-scale de novo studies 5, 6 have identified genes with recurrent, highly damaging mutations that cluster in pathways involved in transcriptional regulation, chromatin modification, and synaptic function. Initial studies in schizophrenia have been underpowered to implicate rare variants in a specific gene, although they have found convergent evidence for association of both damaging de novo and singleton variants in gene sets of the postsynaptic density (PSD) proteins, calcium channels, targets of the fragile X mental retardation protein (FMRP), and chromatin remodeling genes. [7] [8] [9] Several case-control and family-based sequencing studies of BD are ongoing, but only a limited number have been published. [10] [11] [12] [13] Two family studies 12, 13 of the Amish population found evidence for partial segregation of a number of variants but little convergence on a specific gene or a linkage location. Similar results were found by Collins et al, 10 who performed exome sequencing of a large pedigree without conclusively identifying variants of large effect, and by Cruceanu et al, 11 who studied 25 pedigrees with lithium-responsive BD and also found limited evidence for cosegregation at the level of variants or genes across families. The largest study 14 of BD to date performed whole-genome sequencing of 200 individuals from 41 families with BD, finding evidence for an excess of rare variants in pathways associated with γ-aminobutyric acid and calcium channel signaling. The results of these early studies suggest that the pattern of complex inheritance in BD seen with common variants may also hold for rare variants, with potentially many risk alleles of modest effect distributed across large numbers of genes and noncoding regions. Given the inherent challenges of studying rare variants with currently available sample sizes, 15 we used a hybrid approach to exome sequencing in BD by sequencing 8 multiplex families as an initial discovery strategy, followed by a case-control meta-analysis of 3541 BD cases and 4774 controls.
Methods

Primary Family and Case-Control Samples
Cases for the family sample were ascertained at The Johns Hopkins University as part of a genetic linkage study of BD, 16 which has been approved by The Johns Hopkins University Institutional Review Board. Written informed consent was obtained from all participants. The sequenced family sample was selected to include pedigrees with more than 4 affected members carrying the diagnosis of BD type I (BD-I), BD type II (BD-II), or schizoaffective disorder, bipolar type. One additional family with multiple cases of BD-II was also selected. The 8 pedigrees are shown in the Figure. They include a mean of 6.9 affected individuals, and 36 of 55 were sequenced. The primary case-control sample (1135 cases and 1142 controls) was generated from an exome sequencing study of BD and controls, referred to as the Rare Bipolar Loci Identification Through Synaptome Sequencing (RareBLISS) exome study (described more fully in the eText in the Supplement). DNA from both cases and controls was isolated from lymphoblastoid cell lines. All cases and controls were of self-reported European ancestry.
Exome Sequencing
We performed exome capture using capture arrays (NimbleGen EZ Exome, version 1 and version 2; Roche), followed by standard alignment and variant calling with the Genome Analysis 
Family Analysis
For the family-based analysis, we used a filtering approach to identify low-frequency (minor allele frequency [MAF] <1%) damaging variants (defined by the nonsynonymous broad annotation) that segregated with all affected relatives while allowing for one missing genotype per family. This strategy was motivated by a hypothesis that risk variants of moderate to high penetrance would be shared within families but not necessarily across different families given the failure of prior linkage investigations to identify replicable findings.
Case-Control Analysis
From the family analysis, we identified rare and damaging segregating variants that were tested in the RareBLISS casecontrol sample. For single-variant tests, we used logistic regression with the Firth penalized likelihood method, which can incorporate discrete and continuous covariates and provides a more robust estimate of the effect size estimates when data are sparse. 20 We included as covariates 4 ancestry-based principal components (derived from common variants extracted from the exome sequencing data set using the software 
Meta-analysis
We further examined the variants and genes implicated by the family analysis in 2 additional case-control samples (eText in the Supplement). The first comprised 1022 cases with BD and 2220 controls from Sweden. 22 The second consisted of an interim data freeze from the Bipolar Research in Deep Genome and Epigenome Sequencing (BRIDGES) Study, comprising whole-genome sequencing results for 1388 cases with BD and 1412 controls, all of European ancestry (eText in the Supplement). Phenotypic details are provided in the eText in the Supplement. The analyses of both additional data sets were performed in a manner similar to what was done in Rare-BLISS using penalized logistic regression for single-variant analyses and PLINK/SEQ burden tests for the gene-level association tests. Because joint analysis has been shown to be more powerful than replication, 23 we performed variant-level and gene-level tests of association, followed by fixed-effects meta-analysis of the results across all 3 samples using METAL (http://www .sph.umich.edu/csg/abecasis/metal/). 
Gene Set Enrichment Analysis
Genes with segregating variants were found to include a number of genes previously observed in de novo investigations of autism and schizophrenia, and some were also localized to the PSD. To test for specific enrichment of these gene sets, we used the curated list from prior studies 5, 8 that summarized genes with de novo nonsense and missense variants in autism (n = 1781), schizophrenia (n = 670), and intellectual disability (n = 141) studies, as well as genes encoding proteins found in the PSD (n = 1398) and the FMRP pathway (n = 795). We subsequently tested whether genes with a segregating variant were enriched for any of these 3 categories by randomly selecting an equal number of genes captured by our exome study while matching by the following 3 potentially confounding metrics: cumulative exon length (±20%), sequence coverage (±20%), and a gene-specific corrected measure of intolerance to missense variation (missense z score). The latter represents a standardized measure of the deviation between observed and expected missense variants found in the Exome Aggregation Consortium database. 25 We performed 10 000
permutations and counted the number of times that randomly selected genes were found in each of the 3 gene sets.
We then compared our observed counts of overlap with the 3 gene sets with this null distribution to obtain empirical P values. As an additional step to evaluate the potential role of background variation in our results, we also obtained a curated list of genes (n = 1215) found to harbor de novo variants (missense and loss of function) in well siblings from simplex families with autism. 5 We tested for enrichment of these "control" de novo genes using the same matched permutation procedure.
Results
Family Analysis
We first searched for variants of moderate to high penetrance in 8 multiplex families by sequencing at least 4 affected members in each family ( Figure) . A total of 7551 variants were found to segregate as heterozygotes in at least 1 family, ranging from 511 to 1683 variants per family, reflecting the size of the pedigrees and the decreased likelihood of sharing variants with an increased number of sequenced cases ( Table 1 ). Filtering for rare (MAF <1%), damaging variants as defined by the NS broad category led to the identification of 84 variants that segregated in at least 1 family, including 23 variants that further met the NS strict criteria and 5 variants that were disruptive. The 84 segregating variants were found in 82 independent genes (shown fully in eTable 1 in the Supplement), with 2 genes (LAMA4 and OBSCN) having 2 segregating variants. The 2 segregating variants in LAMA4 were in the same family, while the 2 variants in OBSCN were found in independent families. However, both genes are large and evolutionarily unconstrained, 26 increasing the likelihood that they could be false-positives.
Case-Control Follow-up
To obtain convergent evidence for association with BD, we examined whether segregating variants showed consistent evidence for association in 3 ongoing case-control studies of BD in individuals of European ancestry. These included the Rare-BLISS (1135 cases and 1142 controls), Sweden (1018 cases and 2220 controls), and BRIDGES (1388 cases and 1412 controls) studies. Each study was analyzed separately, and the results were combined in a fixed-effects meta-analysis.
Variant-Level Analysis
We performed penalized logistic regression of the 84 segregating variants in each of the 3 data sets, followed by a fixedeffects meta-analysis that included 3541 cases and 4774 controls (eTable 2 in the Supplement). Of the 84 variants, 49 were present in at least 1 data set, 23 were present in all 3, and 35 were not found in any of them. Variants with a meta-analytic association P < .10 and an odds ratio greater than 1 are listed in Table 2 , which includes 3 variants with nominally significant findings (P < .05) in the MLK4, APPL2, and HSP90AA1 genes.
Gene-Burden Analysis
Given the limited power to identify an association with single variants and the high likelihood of allelic heterogeneity in causal genes, 27 we sought additional evidence for association using gene-based ("burden") association tests of the 82 genes that included at least 1 rare, segregating variant from the family analysis. One-sided burden tests were performed in PLINK/SEQ under 3 frequency classes (MAF <1%, MAF <0.1%, and singletons) and 3 annotation classes (NS broad , NS strict , and disruptive). Association analyses were performed independently in the 3 case-control samples, followed by a fixedeffects meta-analysis. The results of all of the tests performed for the 82 genes are summarized in eTable 3 in the Supplement, with the top findings (P < .05) summarized in Table 3 . No individual P value survived full correction for multiple testing (P < 6.78 × 10 −5
), but 16 genes showed nominal evidence for association (P < .05). Five of these genes were previously found to have de novo damaging variants in investigations of autism (RPGRIP1L, FRAS1, AHNAK, KDM5B, and SLC12A4), while 3 of the genes (SLC4A1, APPL2, and AHNAK) encode proteins localized to the PSD, which has been recently implicated in rare variant studies of schizophrenia. 5, 7, 8, 28 Gene Set Enrichment
The above observations led us to ask whether segregating variants were located within 3 particular gene sets (autism, schizophrenia, and PSD) at a rate that exceeded chance expectation. When all 82 genes with segregating variants under the NS broad model were considered, there were 10 PSD genes, while there were 19 and 11 genes previously identified as harboring de novo missense or nonsense variants in investigations of autism and schizophrenia, respectively (eTable 1 in the Supplement). We tested for overrepresentation of the 82 genes identified by the initial segregation analysis in these 3 gene sets and found evidence for enrichment in the autism set (19 observed vs 10.9 expected, P = .0066) and schizophrenia set (11 observed vs 5.1 expected, P = .0062). The results for the PSD set (10 observed vs 6.9 expected, P = .15) were consistent with chance expectation.
In a further analysis, we tested whether the segregating genes with nominal evidence for association in the casecontrol meta-analyses, in either the variant-level or genelevel tests (n = 19) ( Table 1 and Table 2 ), also showed evidence for enrichment in the same 3 gene sets. This permutation analysis confirmed significant enrichment of the de novo autism gene set (6 observed vs 2.6 expected, P = .028) but not the PSD set (4 observed vs 1.7 expected, P = .09) or the de novo schizophrenia set (1 observed vs 1.0 expected, P = .65).
Given the significance of the autism de novo gene set, we also tested for enrichment of the FMRP pathway and found significant evidence for enrichment in the 82 segregating genes (10 observed vs. 4.4 expected, P = .0076) but not in the subset of 19 genes with nominal evidence of association in the meta-analysis. We further examined the de novo intellectual disability gene set but found no evidence of enrichment (0 observed, P > .99). We note that the significant results for the 82 segregating variants survive correction for the 5 gene sets tested, while the smaller subset of genes with additional nominal significance in the metaanalysis does not.
To evaluate the potential confounding role of "baseline" or expected rates of variation, we tested whether genes implicated by de novo variants found in control siblings were enriched among our segregating variants. The results based on the 82 genes with segregating variants were consistent with chance expectation (10 observed vs 7.6 expected, P = .21).
Discussion
Our study represents one of the first large-scale exome sequencing efforts in BD and one of the first to combine a familybased and case-control design. In each of our selected multiplex families, we found several rare, segregating variants of predicted damaging effect, leading us to seek supportive evidence for association in 3 large-scale, case-control exome sequencing studies. Variant-level and gene-burden analysis pro- a Direction refers to the odds ratios found in the meta-analyzed studies being in the same (+) or opposing (-) direction relative to the risk allele found in the family sample.
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vided supportive nominal evidence (P < .05) for 19 of these genes, although neither variant-based nor gene-burden results met study-wide thresholds for statistical significance. However, we found support for enrichment of segregating variants in genes identified by de novo studies of autism and schizophrenia, with additional evidence for the autism gene set enrichment from case-control data. The 19 genes implicated by segregating variants that showed the strongest evidence for case-control association with BD (Tables 2 and 3 ) included more members of the de novo autism gene set than expected. This enrichment was based on the following 6 genes: HSP90AA1, RPGRIP1L, FRAS1, AHNAK, KDM5B, and SLC12A4. The most strongly implicated of these genes is KDM5B, in which 2 nonsense and 2 missense de novo mutations have been found in sporadic cases with autism.
5 KDM5B (also known as JARIDB1) encodes a histone H3 lysine 4 (H3K4) demethylase that has been linked to neural differentiation in embryonic stem cells. 29 Intriguingly, the recent Psychiatric GWAS Consortium pathway-based analysis of common genetic variation identified histone H3K4 methylation as the most strongly associated pathway with BD.
30
Moreover, histone H3K4 methylation was also found to be the most strongly associated pathway in a cross-disorder analysis of BD, schizophrenia, and major depressive disorder, 34 Overlap between BD and autism is also seen in investigations of rare copy number variation (CNV), with a recent meta-analysis of CNV studies showing evidence for association with BD of 3 CNVs (1q21.1 dup, 3q29 del, and 16p11.2 dup) originally implicated in both autism and schizophrenia. 35, 36 Our study should be seen in light of a number of important limitations. First, a major challenge of rare variant studies is the increasing recognition that very large sample sizes may be necessary to perform a fully powered case-control study. 15 Although our hybrid family-based study, followed by case-control association, was designed to improve power by limiting the genomic search space to variants and genes identified by an initial segregation analysis, power analyses of the combined case-control sample continued to show that the meta-analysis was underpowered to detect the types of effect sizes and allele frequencies found in our study (eFigure in the Supplement). Second, our study exclusively focused on exome variation and thus could not detect any role of rare noncoding variants. Third, although our coverage of the exome is typical of most studies of this type, it is incomplete at approximately 80%, which is an inevitable limitation of current exome capture and sequence technology. Fourth, while we have used widely accepted bioinformatics tools to classify variants as damaging, these tools are probabilistic and imprecise and will likely miss the effect of variants that are tissue specific. Fifth, in focusing only on fully segregating variants, we have not considered less penetrant variants that may be involved in disease susceptibility because these variants would be even more difficult to detect with our available sample size. In sensitivity analyses, we performed a broad analysis of variants shared among 2 or more affected family members and did not find evidence for any association meeting correction for multiple testing or for any similar enrichment compared with the analysis presented in this study. Sixth, our study has relied solely on traditional clinical phenotypes and has not characterized individuals in ways that may align more closely with disease pathophysiology. It is likely that a new generation of "genotypefirst" studies will be needed to delineate which specific phenotypes will constitute molecular subtypes of BD. 37 
Conclusions
In summary, although our study remains underpowered to implicate rare variants in individual genes, we have found preliminary evidence for the overlap of potential autism and schizophrenia risk genes with our segregating variants. These results provide further data on shared genetic susceptibility across the major psychiatric disorders.
